AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29349598
Drug: lumretuzumab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose followed by 420 mg in Cohorts 1 and 2; 420 mg without loading dose in Cohort 3) plus paclitaxel (80 mg/m2) every 3 weeks
Trial: 29350386
Drug: VKAs (acenocoumarol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKAs (acenocoumarol, warfarin)
Trial: 29350386
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of dabigatran and rivaroxaban
Trial: 29350463
Drug: Vemurafenib 720
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 720 mg BID
Trial: 29350463
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg BID
Trial: 29351986
Drug: Ruxolitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (oral JAK1/2 inhibitor), at least six cycles administered to 9 patients (27.3%), more than six cycles to 6 patients (18.2%)
Trial: 29351986
Drug: Ruxolitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (oral JAK1/2 inhibitor)
Trial: 29352703
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy
Trial: 29352719
Drug: Unfavorable-risk genetics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfavorable-risk genetics, age ≥ 75 years, race, and treatment choice at enrollment
Trial: 29355412
Drug: Fluoride in
RxNorm normalized name: sulfur hexafluoride intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride in office (drops/tablets and/or varnish) applied by a health care professional by age 1 y
Trial: 29355439
Drug: Minidose glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Minidose glucagon (150 μg, increased to 300 μg if needed)
Trial: 29355904
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate gel, 0.015% for face/scalp and 0.05% for trunk/extremities, applied for treatment of AK
Trial: 29357099
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for mean 21 weeks (sd 5, range 8-24)
Trial: 29357826
Drug: Chair muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chair muscle strength training twice a week for 12 weeks
Trial: 29357841
Drug: ZIKV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZIKV RNA presence testing in various body fluids (blood, urine, semen, vaginal secretion/menstrual blood, rectal swab, oral fluids, tears, sweat, breast milk)
Trial: 29357940
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (psychological preparation and distraction strategy)
Trial: 29358961
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture (VA) group 1 (3 times weekly for 4 weeks)
Trial: 29358961
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture (VA) group 2 (twice weekly for 4 weeks)
Trial: 29358961
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture group (SA; twice weekly for 4 weeks)
Trial: 29360184
Drug: Single-agent post-transplantation
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent post-transplantation cyclophosphamide (PTCy) for MBM grafts
Trial: 29360184
Drug: PTCy, tacrolimus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTCy, tacrolimus, and mycophenolate mofetil (MMF) 30 mg/kg for MPBSC grafts
Trial: 29360184
Drug: PTCy, tacrolimus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTCy, tacrolimus, and MMF 45 mg/kg for MMG grafts
Trial: 29360184
Drug: Combination arms
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination arms (PTCy, tacrolimus, and MMF)
Trial: 29360414
Drug: Radiotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy after chemotherapy
Trial: 29360462
Drug: Large SPSS
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large SPSS (L-SPSS, ≥8 mm)
Trial: 29360462
Drug: SPSS (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPSS (both L-SPSS and S-SPSS)
Trial: 29360526
Drug: Ibrutinib therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib therapy, short-term, dosage and duration not specified
Trial: 29361097
Drug: 4.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 g/day multimatrix mesalamine for 8 weeks (induction period)
Trial: 29361097
Drug: 2.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day multimatrix mesalamine for 12 additional months (maintenance period)
Trial: 29361097
Drug: Fluctuating between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluctuating between complete and partial remission during maintenance treatment
Trial: 29361435
Drug: SGM-101 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGM-101 (10 mg) administered intravenously 4 days before surgery
Trial: 29361470
Drug: Prexasertib 105
RxNorm normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prexasertib 105 mg/m administered intravenously
Trial: 29362251
Drug: Evaluation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of key performance measures such as time to first ECG, receipt of troponin testing, receipt of reperfusion therapy for ST segment elevation ACS, provision of angiography for troponin-positive patients.
Trial: 29362665
Drug: Paricalcitol (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (Vitamin D receptor activation)
Trial: 29362685
Drug: Artesunate-amodiaquine fixed-dose
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artesunate-amodiaquine fixed-dose combination tablets (ASAQ Winthrop®)
Trial: 29362724
Drug: Suboptimal antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal antiretroviral therapy adherence (<100%)
Trial: 29362724
Drug: Optimal antiretroviral
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal antiretroviral therapy adherence (≥100%)
Trial: 29363235
Drug: E7777 (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7777 (6, 12, and 9 μg/kg/day)
Trial: 29363235
Drug: E7777 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7777 (9 μg/kg/day)
Trial: 29363446
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue DNA vaccine (TVDV) formulated in Vaxfectin
Trial: 29363651
Drug: Remote Ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Ischemic Conditioning (RIC) consisting of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuffs on bilateral upper limbs twice a day for 90 days.
Trial: 29364886
Drug: VRC01LS intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01LS intravenous (IV) infusion at 20 mg/kg
Trial: 29364886
Drug: VRC01LS intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01LS intravenous (IV) infusion at 40 mg/kg
Trial: 29364886
Drug: VRC01LS intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01LS intravenous (IV) administration at 5 mg/kg
Trial: 29364886
Drug: VRC01LS subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01LS subcutaneous (SC) administration at 5 mg/kg
Trial: 29364886
Drug: VRC01LS IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01LS IV dose range of 5-40 mg/kg
Trial: 29365099
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 µg administered by subcutaneous injection daily for 104 weeks
Trial: 29366510
Drug: Targeted treatment
RxNorm normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatment based on molecular alterations identified from tumor biopsy
Trial: 29366960
Drug: Gemcitabine (1000-1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000-1250 mg/kg over 30-60 min i.v infusion)
Trial: 29368271
Drug: Anti-CCP2 antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CCP2 antibody positive patients (Gp1-3)
Trial: 29368271
Drug: Anti-CCP2 antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CCP2 antibody negative patients
Trial: 29368632
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of suPAR and syndecan-4 with Pneumonia Severity Index
Trial: 29368632
Drug: suPAR ≥10.22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR ≥10.22 ng/mL and syndecan-4 ≤6.68 ng/mL
Trial: 29369091
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2.5 µg·kg
Trial: 29369091
Drug: Oral pentobarbital
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentobarbital 5 mg·kg
Trial: 29369091
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1 µg·kg (rescue sedation)
Trial: 29369664
Drug: Escitalopram, Duloxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, Duloxetine, or Cognitive Behavior Therapy (CBT)
Trial: 29370183
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) resumption after ICH
Trial: 29370229
Drug: Anticoagulants (ACs)
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (ACs) with or without antiplatelet (AP) therapy
Trial: 29370795
Drug: Postpartum weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum weight retention intervention including six weeks of interactive daily health texting, exercise assistance with baby carrier, home exercise program, pedometer provision, two live healthy eating and baby feeding workshops, and two 45-min home visits over one year
Trial: 29370811
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg prednisolone daily added to standard of care
Trial: 29371177
Drug: Automated mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated mobile phone-based personalized daily step goals
Trial: 29371475
Drug: Everolimus, 10
RxNorm normalized name: Everolimus, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus, 10 mg daily
Trial: 29371864
Drug: Loratadine tablets
RxNorm normalized name: Loratadine Tablets
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine tablets
Trial: 29372409
Drug: Solutions provided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solutions provided group
Trial: 29372409
Drug: Solutions withheld
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solutions withheld group
Trial: 29372461
Drug: Irinotecan (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (135 mg/m²), oxaliplatin, and S-1 (OIS) regimen
Trial: 29373071
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg once per day until disease progression
Trial: 29373602
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg BID apixaban
Trial: 29373602
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg BID apixaban
Trial: 29373711
Drug: Pioglitazone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone therapy for 24 weeks
Trial: 29373984
Drug: 12-week progressive,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-week progressive, strength and neuromuscular exercise group (SNG) with supervised training twice weekly
Trial: 29373998
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (laser group)
Trial: 29373998
Drug: Light-emitting diode
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-emitting diode (LED) therapy (LED group)
Trial: 29375477
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of r-hFSH/r-hLH (900/450 IU)
Trial: 29375477
Drug: Freeze-dried formulation
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried formulation of r-hFSH/r-hLH (900/450 IU)
Trial: 29377748
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (650 mg EPA and 350 mg DHA daily)
Trial: 29377953
Drug: Ganciclovir gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir gel, 0.15% 1cc 5 times a day for 6 weeks
Trial: 29378056
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 36.6 mg·kg-1·d-1 during early gestation
Trial: 29378056
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 50.3 mg·kg-1·d-1 during late gestation
Trial: 29378547
Drug: Oral antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotic treatments (APT)
Trial: 29378547
Drug: Other injectable
RxNorm normalized name: dihematoporphyrin ether Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other injectable antipsychotic treatments (APT)
Trial: 29378547
Drug: Oral APT
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral APT
Trial: 29380442
Drug: Locoregional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional treatment (including Radiofrequency ablation and combination therapy)
Trial: 29380442
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RFA and transarterial chemoembolization
Trial: 29380445
Drug: Self-reported non-adherence
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported non-adherence to immunosuppressive medication
Trial: 29380445
Drug: Medication knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication knowledge and trough levels
Trial: 29381435
Drug: Selinexor 80
RxNorm normalized name: SELINEXOR 80MG WEEKLY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly
Trial: 29381834
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy consisting of thermal modalities, tissue mobilization, and upper extremity mobility exercises, with 8 weekly in-person sessions.
Trial: 29382391
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lopinavir/ritonavir and recombinant interferon-β1b with standard supportive care
Trial: 29382510
Drug: Preoperative Renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative Renal Functional Reserve (RFR) measured by high oral protein load test
Trial: 29382957
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment (level 1 treatment)
Trial: 29383572
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day) for 104 weeks
Trial: 29383782
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) completely withdrawn
Trial: 29383782
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) stepped-down to a reduced dose
Trial: 29384473
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEG and fMRI data
Trial: 29385166
Drug: Locomotor training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locomotor training (LT) on a treadmill using body-weight support for 80 daily one-hour sessions
Trial: 29385376
Drug: 19-28z CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19-28z CAR T cells infusion
Trial: 29385444
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline (100 mg q12h)
Trial: 29385444
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone (2 g q24h)
Trial: 29385837
Drug: L-selectin
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-selectin
Trial: 29385837
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor-binding protein 3
Trial: 29385837
Drug: Heparin cofactor
RxNorm normalized name: Heparin cofactor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin cofactor 2
Trial: 29386196
Drug: Ibrutinib in
RxNorm normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide) at 840 mg daily
Trial: 29386196
Drug: Ibrutinib in
RxNorm normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib in combination with R-ICE
Trial: 29386195
Drug: Galinpepimut-S (multivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galinpepimut-S (multivalent WT1 peptide vaccine) administered as 6 vaccinations over 10 weeks, with potential for 6 additional monthly doses if in CR1.
Trial: 29386249
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitor therapy
Trial: 29387020
Drug: Attachment-Based Compassion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-Based Compassion Therapy (ABCT) combined with treatment as usual (TAU)
Trial: 29387020
Drug: Relaxation (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation (active control group) combined with treatment as usual (TAU)
Trial: 29387473
Drug: H5VLP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5VLP vaccine co-administered with Alhydrogel
Trial: 29387473
Drug: H5VLP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5VLP vaccine co-administered with GLA-SE
Trial: 29388903
Drug: FGln tracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGln tracer (mean, 244 MBq ± 118, <100 μg) administered intravenously
Trial: 29389078
Drug: 2% Tapinarof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Tapinarof cream
Trial: 29389078
Drug: 1% Tapinarof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Tapinarof cream
Trial: 29389360
Drug: hESC-derived cardiovascular
RxNorm normalized name: hESC-derived RPE
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hESC-derived cardiovascular progenitors (median dose 8.2 million)
Trial: 29389444
Drug: Pantoprazole, ~1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole, ~1.2 mg/kg lean body weight (LBW)
Trial: 29389444
Drug: Pantoprazole, LBW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole, LBW dosing
Trial: 29391051
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of high-dose amoxicillin
Trial: 29391051
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of high-dose amoxicillin (reference standard)
Trial: 29391374
Drug: wP (whole-cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wP (whole-cell pertussis) vaccine as the first vaccine dose
Trial: 29391374
Drug: aP (subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aP (subunit acellular pertussis) vaccine as the first vaccine dose